Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod

Journal of Immunology

Volumn 173, Issue 5, 2004, Pages 3051-3061

  Palamara, Francesca ^a,b,c   Meindl, Simone ^a   Holcmann, Martin ^a,b   Lührs, Petra ^a   Stingl, Georg ^a,b   Sibilia, Maria ^a,b  

^a Universitatsklinik fur Dermatologie   (Austria)

^b Competence Ctr Biomol Therapeut ^*  (Austria)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; GLYCOPROTEIN P 15095; IMIQUIMOD; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER TISSUE; CELL ACTIVATION; CELL ISOLATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CREAM; DENDRITIC CELL; DERMIS; DRUG EFFECT; DRUG FORMULATION; DRUG POTENCY; FEMALE; IMMUNOMODULATION; LYMPHOID ORGAN; MELANOMA; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PHENOTYPE; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN; SPLEEN;

EID: 4344697150     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.173.5.3051     Document Type: Article

References (63)

1. Banchereau, J., F. Briere, C. Caux, J. Davoust, S. Lebecque, Y. J. Liu, B. Pulendran, and K. Palucka. 2000. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18:767.
2. Mellman, I., and R. M. Steinman. 2001. Dendritic cells: specialized and regulated antigen processing machines. Cell 106:255.
3. Ardavin, C., G. Martinez del Hoyo, P. Martin, F. Anjuere, C. F. Arias, A. R. Marin, S. Ruiz, V. Parrillas, and H. Hernandez. 2001. Origin and differentiation of dendritic cells. Trends Immunol. 22:691.
4. Vandenabeele, S., and L. Wu. 1999. Dendritic cell origins: puzzles and paradoxes. Immunol. Cell. Biol. 77:411.
5. Shortman, K., and Y. J. Liu. 2002. Mouse and human dendritic cell subtypes. Nat. Rev. Immunol. 2:151.
6. Wollenberg, A., M. Wagner, S. Gunther, A. Towarowski, E. Tuma, M. Moderer, S. Rothenfusser, S. Wetzel, S. Endres, and G. Hartmann. 2002. Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J. Invest. Dermatol. 119:1096.
7. Bangert, C., J. Friedl, G. Stary, G. Stingl, and T. Kopp. 2003. Immunopathologic features of allergic contact dermatitis in humans: participation of plasmacytoid dendritic cells in the pathogenesis of the disease? J. Invest. Dermatol. 121:1409.
8. Lennert, K., and W. Remmele. 1958. Karyometrische Untersuchungen an Lymphknotenzellen des Menschen. I. Mitt Germinoblasten, Lymphoblasten und Lymphozyten. Acta Haematol. 19:99.
9. + peripheral blood dendritic cells are differentially regulated by cytokines. J. Immunol. 163:3250.
10. Cella, M., D. Jarrossay, F. Facchetti, O. Alebardi, H. Nakajima, A. Lanzavecchia, and M. Colonna. 1999. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat. Med. 5:919.
11. Siegal, F. P., N. Kadowaki, M. Shodell, P. A. Fitzgerald-Bocarsly, K. Shah, S. Ho, S. Antonenko, and Y. J. Liu. 1999. The nature of the principal type 1 interferon-producing cells in human blood. Science 284:1835.
12. Hochrein, H., M. O'Keeffe, and H. Wagner. 2002. Human and mouse plasmacytoid dendritic cells. Hum. Immunol. 63:1103.
13. Galy, A., I. Christopherson, G. Ferlazzo, G. Liu, H. Spits, and K. Georgopoulos. 2000. Distinct signals control the hematopoiesis of lymphoid-related dendritic cells. Blood 95:128.
14. Abb, J., H. Abb, and F. Deinhardt. 1983. Phenotype of human α-interferon producing leucocytes identified by monoclonal antibodies. Clin. Exp. Immunol. 52:179.
15. Kadowaki, N., S. Antonenko, J. Y. Lau, and Y. J. Liu. 2000. Natural interferon α/β-producing cells link innate and adaptive immunity. J. Exp. Med. 192:219.
16. Asselin-Paturel, C., A. Boonstra, M. Dalod, I. Durand, N. Yessaad, C. Dezutter-Dambuyant, A. Vicari, A. O'Garra, C. Biron, F. Briere, et al. 2001. Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat. Immunol. 2:1144.
17. Bjorck, P. 2001. Isolation and characterization of plasmacytoid dendritic cells from Flt3 ligand and granulocyte-macrophage colony-stimulating factor-treated mice. Blood 98:3520.
18. + cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J. Exp. Med. 194:1171.
19. + cells in murine bone marrow and spleen does not belong to the B cell lineage but has dendritic cell characteristics. Eur. J. Immunol. 32:686.
20. + plasmacytoid dendritic cells develop independently of the T-cell lineage. Blood 100:2852.
21. + dendritic cells endowed with type 1 interferon production capacity and tolerogenic potential. Blood 100:383.
22. + dendritic cells only after microbial stimulus. J. Exp. Med. 196:1307.
23. Vremec, D., J. Pooley, H. Hochrein, L. Wu, and K. Shortman. 2000. CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen. J. Immunol. 164:2978.
24. Okada, T., Z. X. Lian, M. Naiki, A. A. Ansari, S. Ikehara, and M. E. Gershwin. 2003. Murine thymic plasmacytoid dendritic cells. Eur. J. Immunol. 33:1012.
25. Lian, Z. X., T. Okada, X. S. He, H. Kita, Y. J. Liu, A. A. Ansari, K. Kikuchi, S. Ikehara, and M. E. Gershwin. 2003. Heterogeneity of dendritic cells in the mouse liver: identification and characterization of four distinct populations. J. Immunol. 170:2323.
26. Akira, S., K. Takeda, and T. Kaisho. 2001. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2:675.
27. Akira, S., and H. Hemmi. 2003. Recognition of pathogen-associated molecular patterns by TLR family. Immunol. Lett. 85:85.
28. Gibson, S. J., J. M. Lindh, T. R. Riter, R. M. Gleason, L. M. Rogers, A. E. Fuller, J. L. Oesterich, K. B. Gorden, X. Qiu, S. W. McKane, et al. 2002. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell. Immunol. 218:74.
29. Hemmi, H., T. Kaisho, O. Takeuchi, S. Sato, H. Sanjo, K. Hoshino, T. Horiuchi, H. Tomizawa, K. Takeda, and S. Akira. 2002. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3:196.
30. Heil, F., H. Hemmi, H. Hochrein, F. Ampenberger, C. Kirschning, S. Akira, G. Lipford, H. Wagner, and S. Bauer. 2004. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 303:1526.
31. Diebold, S. S., T. Kaisho, H. Hemmi, S. Akira, and E. S. C. Reis. 2004. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303:1529.
32. Stanley, M. A. 2002. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin. Exp. Dermatol. 27:571.
33. Miller, R. L., J. F. Gerster, M. L. Owens, H. B. Slade, and M. A. Tomai. 1999. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int. J. Immunopharmacol. 21:1.
34. Rhodes, J. 2002. Discovery of immunopotentiatory drugs: current and future strategies. Clin. Exp. Immunol. 130:363.
35. Megyeri, K., W. C. Au, I. Rosztoczy, N. B. Raj, R. L. Miller, M. A. Tomai, and P. M. Pitha. 1995. Stimulation of interferon and cytokine gene expression by imiquimod and stimulation by Sendai virus utilize similar signal transduction pathways. Mol. Cell. Biol. 15:2207.
36. Kono, T., S. Kondo, S. Pastore, G. M. Shivji, M. A. Tomai, R. C. McKenzie, and D. N. Sauder. 1994. Effects of a novel topical immunomodulator, imiquimod, on keratinocyte cytokine gene expression. Lymphokine Cytokine Res. 13:71.
37. Ito, T., R. Amakawa, T. Kaisho, H. Hemmi, K. Tajima, K. Uehira, Y. Ozaki, H. Tomizawa, S. Akira, and S. Fukuhara. 2002. Interferon-α and interleukin-12 are induced differentially by Toll-like receptor 7 ligands ligands in human blood dendritic cell subsets. J. Exp. Med. 195:1507.
38. Testerman, T. L., J. F. Gerster, L. M. Imbertson, M. J. Reiter, R. L. Miller, S. J. Gibson, T. L. Wagner, and M. A. Tomai. 1995. Cytokine induction by the immunomodulators imiquimod and S-27609. J. Leukocyte Biol. 58:365.
39. Harrison, C. J., R. L. Miller, and D. I. Bernstein. 1994. Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs. Antimicro.b Agents Chemother. 38:2059.
40. Harrison, C. J., R. L. Miller, and D. I. Bernstein. 2001. Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine. Vaccine 19:1820.
41. Sidky, Y., G. Bryan, J. Weeks, J. Hatcher, and E. Borden. 1990. Effect of treatment with an oral interferon inducer, imidazoquinolamine (R-837) on the growth of mouse bladder carcinoma FCB. J Interferon Res. 10:S123 (Abstr.).
42. Sidky, Y. A., E. C. Borden, C. E. Weeks, M. J. Reiter, J. F. Hatcher, and G. T. Bryan. 1992. Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine. Cancer Res. 52:3528.
43. Suzuki, H., B. Wang, G. M. Shivji, P. Toto, P. Amerio, M. A. Tomai, R. L. Miller, and D. N. Sauder. 2000. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J. Invest. Dermatol. 114:135.
44. Tomai, M. A., S. J. Gibson, L. M. Imbertson, R. L. Miller, P. E. Myhre, M. J. Reiter, T. L. Wagner, C. B. Tamulinas, J. M. Beaurline, J. F. Gerster, et al. 1995. Immunomodulating and antiviral activities of the imidazoquinoline S-28463. Antiviral Res. 28:253.
45. Wagner, S. N., C. Wagner, P. Luehrs, T. K. Weimann, R. Kutil, M. Goos, G. Stingl, and A. Schneeberger. 2000. Intracutaneous genetic immunization with autologous melanoma-associated antigen Pmel17/gp100 induces T cell-mediated tumor protection in vivo. J. Invest. Dermatol. 115:1082.
46. Wang, B., A. Rieger, O. Kilgus, K. Ochiai, D. Maurer, D. Foedinger, J. P. Kinet, and G. Stingl. 1992. Epidermal Langerhans cells from normal human skin bind monomeric IgE via FcεRI. J. Exp. Med. 175:1353.
47. Montoya, M., G. Schiavoni, F. Mattei, I. Gresser, F. Belardelli, P. Borrow, and D. F. Tough. 2002. Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood 99:3263.
48. Bottcher, T., M. von Mering, S. Ebert, U. Meyding-Lamade, U. Kuhnt, J. Gerber, and R. Nau. 2003. Differential regulation of Toll-like receptor mRNAs in experimental murine central nervous system infections. Neurosci. Lett. 344:17.
49. Spergel, J. M., E. Mizoguchi, J. P. Brewer, T. R. Martin, A. K. Bhan, and R. S. Geha. 1998. Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice. J. Clin. Invest. 101:1614.
50. + DC correlates with unresponsiveness to imidazoquinolines. Eur. J. Immunol. 33:827.
51. Steinmann, A., J. O. Funk, G. Schuler, and P. von den Driesch. 2000. Topical imiquimod treatment of a cutaneous melanoma metastasis. J. Am. Acad. Dermatol. 43:555.
52. Ahmed, I., and J. Berth-Jones. 2000. Imiquimod: a novel treatment for lentigo maligna. Br. J. Dermatol. 143:843.
53. Hengge, U. R., and R. Stark. 2001. Topical imiquimod to treat intraepidermal carcinoma. Arch. Dermatol. 137:709.
54. Imbertson, L. M., J. M. Beaurline, A. M. Couture, S. J. Gibson, R. M. Smith, R. L. Miller, M. J. Reiter, T. L. Wagner, and M. A. Tomai. 1998. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J. Invest. Dermatol. 110:734.
55. Roake, J. A., A. S. Rao, P. J. Morris, C. P. Larsen, D. F. Hankins, and J. M. Austyn. 1995. Dendritic cell loss from nonlymphoid tissues after systemic administration of lipopolysaccharide, tumor necrosis factor, and interleukin 1. J. Exp. Med. 181:2237.
56. Sidbury, R., N. Neuschler, E. Neuschler, P. Sun, X. Q. Wang, R. Miller, M. Tomai, E. Puscasiu, S. Gugneja, and A. S. Paller. 2003. Topically applied imiquimod inhibits vascular tumor growth in vivo. J. Invest. Dermatol. 121:1205.
57. Kirkwood, J. M., J. G. Ibrahim, V. K. Sondak, M. S. Ernstoff, and M. Ross. 2002. Interferon α-2a for melanoma metastases. Lancet 359:978.
58. Belardelli, F., M. Ferrantini, E. Proietti, and J. M. Kirkwood. 2002. Interferon-α in tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13:119.
59. Agarwala, S. S., and J. M. Kirkwood. 1995. Potential uses of interferon α2 as adjuvant therapy in cancer. Ann. Surg. Oncol. 2:365.
60. + cells from patients with chronic myeloid leukemia and interferon-α up-regulates this expression. Haematologica 85:139.
61. von Stamm, U., E. B. Brocker, M. von Depka Prondzinski, D. J. Ruiter, P. Rumke, C. Broding, S. Carrel, and F. J. Lejeune. 1993. Effects of systemic interferon-α (IFN-α) on the antigenic phenotype of melanoma metastases: EORTC melanoma group cooperative study no. 18852. Melanoma Res. 3:173.
62. Slaton, J. W., P. Perrotte, K. Inoue, C. P. Dinney, and I. J. Fidler. 1999. Interferon-α-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin. Cancer Res. 5:2726.
63. Ezekowitz, R. A., J. B. Mulliken, and J. Folkman. 1992. Interferon α-2a therapy for life-threatening hemangiomas of infancy. N. Engl. J. Med. 326:1456.